Cargando…
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative
INTRODUCTION: SCAN-LEAF, part of the I-O Optimise initiative, is a retrospective, longitudinal study investigating the epidemiology, clinical care, and outcomes for patients with NSCLC in Scandinavia. We report overall survival (OS) trends for patients diagnosed with NSCLC in Sweden and Denmark betw...
Autores principales: | Ekman, Simon, Horvat, Pia, Rosenlund, Mats, Kejs, Anne Mette, Patel, Dony, Juarez-Garcia, Ariadna, Lacoin, Laure, Daumont, Melinda J., Penrod, John R., Brustugun, Odd Terje, Sørensen, Jens Benn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474201/ https://www.ncbi.nlm.nih.gov/pubmed/34590017 http://dx.doi.org/10.1016/j.jtocrr.2021.100165 |
Ejemplares similares
-
Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I‐O Optimise initiative
por: Soares, Marta, et al.
Publicado: (2021) -
Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative
por: Snee, Michael, et al.
Publicado: (2021) -
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative
por: Soares, Marta, et al.
Publicado: (2020) -
Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative
por: Snee, Michael, et al.
Publicado: (2021) -
Superior Sulcus Tumors Invading the Spine: Multimodal Treatment Outcomes From the Preimmunotherapy Era
por: Unal, Semih, et al.
Publicado: (2023)